European Cancer Organisation shared a post on LinkedIn:
“Precision cancer medicine is reshaping cancer care in Europe. But access to molecular testing, biomarker-driven therapies and innovative diagnostics still depends too heavily on where a patient lives.
Our new policy action report explores:
- The barriers limiting equitable access across Europe
- The role of data infrastructure and real-world evidence
- How stronger collaboration between cancer centres can improve implementation
- Why sustained EU political and financial support remains essential
The report brings together recommendations from experts, policymakers, clinicians, researchers and patient advocates working to make precision cancer medicine more accessible and sustainable across European health systems.
Read the full publication.”
Other articles from European Cancer Organisation on OncoDaily.